Phase 2 N=85 S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone
Breast Cancer · Metastatic Cancer
Primary: Progression-free Survival — 10.3; 15.3 weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=150 A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy
Edematous Fibrosclerotic Panniculopathy (EFP)
Primary: Investigator Global Assessment of Aesthetic Improvement — 0.7; 0.9; 1.1; 0.5 units on a scale
Phase 2 N=30 Topiramate in Adolescents With Severe Obesity
Obesity, Morbid · Obesity · Weight Loss
Primary: Percent Change From Baseline in Body Mass Index at 28-Weeks — -2.74; -0.85 % change BMI
Phase 2 N=21 Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
Neurofibromatosis · Neurofibromas
Primary: Disease Response — 13; 0; 0; 0 Participants
Phase 2 N=130 A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
Diabetic Kidney Disease
Primary: Change From Baseline in Urinary Albumin/Creatinine Ratio (UACR) at Week 24 — 1.12; 0.87; 0.85; 0.91 milligram/gram (mg/g)
Phase 2 N=22 Hydroxyproline Influence on Oxalate Metabolism
Hyperoxaluria
Primary: Mean Percent Conversion of Hydroxyproline (Hyp) to Urinary Oxalate (UOx) — 12.8; 32.9; 14.8 percent converted
Phase 2 N=74 Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
Recurrent Fallopian Tube Cancer · Recurrent Ovarian Epithelial Cancer · Recurrent Primary Peritoneal Cavity Cancer
Primary: Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria — 9; 0 participants
Phase 2 N=197 A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy
Painful Diabetic Neuropathy · Diabetes
Primary: Summary of Neuropathic Pain Symptom Inventory (NPSI) — 34.44 units on a scale
Phase 2 N=500 Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Breast Cancer · Menopausal Symptoms
Primary: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes — 8.4; 10.00; 7.10; 3.42 ng/mL
Phase 2 N=248 Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
Asthma
Primary: Peak Change From Baseline in FEV1 Within 3 Hours Post-dosing on Day 15 — 0.284; 0.261; 0.252; 0.237 Liter
Phase 2 N=143 Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia
Pneumonia, Bacterial
Primary: Change From Baseline in Clinical Pulmonary Infection Score (CPIS) For Each Patient, Value Obtained From a Daily Assessment Over the 10 Day Study Period Was Compared to…
Phase 2 N=85 S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer
Lung Cancer
Primary: Feasibility of Pharmacogenomics-based Treatment Assignment in the Cooperative Group Setting — 71 Participants
Phase 2 N=30 Rituximab in IgG4-RD: A Phase 1-2 Trial
Retroperitoneal Fibrosis · Autoimmune Pancreatitis · Sialadenitis
Primary: IgG4-RD RI Score at Baseline and Six Months After Rituxan Treatment — 11; 1 units on a scale
Phase 2 N=68 A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
Prostatic Neoplasms
Primary: Patient Bone Scan Response Rate — 22.2; 57.9; 50.0; 0 Percentage — p=0.0109
Phase 2 N=46 Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Polycystic Kidney, Autosomal Dominant
Primary: Safety Assessments Based on Vital Signs, Electrocardiogram (ECG's), Clinical Laboratory Tests, Physical Examinations Are Reported as Adverse Events (AEs) Upon Study…